» Authors » Erik Dupont

Erik Dupont

Explore the profile of Erik Dupont including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 673
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Eschlboeck S, Goebel G, Eckhardt C, Fanciulli A, Raccagni C, Djamshidian A, et al.
Mov Disord Clin Pract . 2023 Sep; 10(9):1368-1376. PMID: 37772304
Background: Multiple system atrophy (MSA) is a devastating disease characterized by a variable combination of motor and autonomic symptoms. Previous studies identified numerous clinical factors to be associated with shorter...
2.
Bebbington N, Jorgensen T, Dupont E, Micheelsen M
EJNMMI Phys . 2021 Mar; 8(1):29. PMID: 33743091
Background: Applied tube voltage (kilovolts, kV) and tube current (milliampere seconds, mAs) affect CT radiation dose and image quality and should be optimised for the individual patient. CARE kV determines...
3.
Nasser A, Moller A, Hellmund V, Thorborg S, Jespersgaard C, Bjerrum O, et al.
Pain . 2018 Feb; 159(6):1012-1024. PMID: 29470312
Human studies have demonstrated a correlation between noncoding polymorphisms of "the pain protective" haplotype in the GCH1 gene that encodes for GTP cyclohydrolase I (GTPCH1)-which leads to reduced tetrahydrobiopterin (BH4)...
4.
Nasser A, Bjerrum O, Heegaard A, Moller A, Larsen M, Dalboge L, et al.
Mol Pain . 2013 Feb; 9:5. PMID: 23421753
Background: GTP cyclohydrolase 1 (GTP-CH1), the rate-limiting enzyme in the synthesis of tetrahydrobiopterin (BH4), encoded by the GCH1 gene, has been implicated in the development and maintenance of inflammatory pain...
5.
Wenning G, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al.
Lancet Neurol . 2013 Feb; 12(3):264-74. PMID: 23391524
Background: Multiple system atrophy (MSA) is a fatal and still poorly understood degenerative movement disorder that is characterised by autonomic failure, cerebellar ataxia, and parkinsonism in various combinations. Here we...
6.
Guldbrand Rasmussen V, Ostergaard K, Dupont E, Hvitfeldt Poulsen S
Mov Disord . 2011 Jun; 26(5):801-6. PMID: 21671508
Objectives: Several observational studies suggest an association between treatment with ergoline-derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta-analysis....
7.
Kollensperger M, Geser F, Ndayisaba J, Boesch S, Seppi K, Ostergaard K, et al.
Mov Disord . 2010 Oct; 25(15):2604-12. PMID: 20922810
Multiple system atrophy (MSA) is a Parkinson's Disease (PD)-like α-synucleinopathy clinically characterized by dysautonomia, parkinsonism, cerebellar ataxia, and pyramidal signs in any combination. We aimed to determine whether the clinical...
8.
Rasmussen V, Poulsen S, Dupont E, Ostergaard K, Safikhany G, Egeblad H
J Heart Valve Dis . 2009 Oct; 18(4):463-9. PMID: 19852154
Background And Aim Of The Study: Ergot-derived dopamine agonists (DAs) are used in the treatment of Parkinson's disease, but may be associated with valvular heart disease and pulmonary hypertension. The...
9.
Guldbrand Rasmussen V, Hvitfeldt Poulsen S, Dupont E, Ostergaard K, Safikhany G, Egeblad H
Eur J Echocardiogr . 2008 May; 9(6):803-8. PMID: 18490274
Aims: Ergot-derived dopamine agonists (EDDA) induce fibrotic heart valve disease. We aimed to investigate whether EDDA treatment also affects left ventricular (LV) function. Methods And Results: Myocardial function was evaluated...
10.
Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, et al.
Mov Disord . 2008 Apr; 23(8):1093-9. PMID: 18442131
The clinical diagnosis of multiple system atrophy (MSA) is fraught with difficulty and there are no pathognomonic features to discriminate the parkinsonian variant (MSA-P) from Parkinson's disease (PD). Besides the...